RE: Smoking Tobacco and Collective Myopia
Dear Editor: We appreciate Dr Schütz, Dr Scheef, and Mr Sepehry's interest and extensive comment on our review articles published in The Canadian Journal of Psychiatry earlier this year and we agree that smoking as a confounding factor has not been well-studied in psychiatric research. However, a discussion of tobacco use as a confounder in psychiatric studies is beyond the scope of our reviews, which were focused on understanding tobacco use and cessation in mental health and addictive disorder populations.
We would like to highlight a few historical examples of the confounding effects of tobacco use in psychiatric studies:
In the late 1970s, it was believed that the observation of reduced platelet monoamine oxidase (MAO) activity in patients with chronic schizophrenia was a biological deficit inherent to the diagnosis of schizophrenia.
1 Domino 2 discussed more than 20 years after this initial publication that cigarette smoking was the confounding factor which reduced MAO enzyme activity in schizophrenia relative to control subjects, given the higher rates of tobacco use in these patients.
Numerous studies have demonstrated the higher rates of cigarette smoking in patients with mood disorders. 3 In a recently study 4 of the nicotinic receptor antagonist mecamylamine in treatment refractory unipolar depressed subjects, our group showed that nonsmoking status was associated with better antidepressant responses to mecamylamine than placebo. Moreover, in a recent analysis of patients with bipolar disorder pooled from 3 randomized controlled trials, Berk et al 5 found that smokers, compared with nonsmokers, showed a decreased response to mania treatment.
Hibbeln et al 6 discussed that putative abnormalities in essential fatty acid metabolism among patients with schizophrenia may be an artifact of patients' tobacco use and differences in dietary intake of omega-3 fatty acids between smoking and nonsmoking patients.
Several studies [7] [8] [9] [10] have shown that sensorimotor gating deficits in patients with schizophrenia (as assessed operationally by prepulse inhibition [PPI] of the startle reflex) are reduced by smoking abstinence, and enhanced (or even normalized) by acute cigarette smoking, which is important to note as most studies that have shown deficits in PPI 11 did not control for time of last cigarette.
These are just a few examples to highlight the recommendation that whenever planning studies of psychiatric populations and study outcomes, smoking status should be taken in consideration. Moreover, these data suggest an important role for nicotinic receptor 12 From a methodological perspective, the inclusion of patients and control subjects parsing for smoking status (for example, current smoker, compared with nonsmoker, both biochemically verified using expired breath carbon monoxide levels and [or] cotinine levels, as appropriate) in psychiatric clinical studies is strongly recommended. We thank Dr Schütz and colleagues for their interest in our articles, and for pointing out this neglected area of investigation in psychiatric research.
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